ACELYRIN INC (SLRN)
US00445A1007 - Common Stock
Top movers in Wednesday's pre-market session
Top movers in Wednesday's pre-market session
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on...
Oversold Conditions For ACELYRIN (SLRN)
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive...
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and...
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC....
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024.
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acelyrin (NASDAQ:SLRN) just reported results for the second quarter of 2024.Ace...
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose...
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
Commit To Purchase ACELYRIN At $5, Earn 99.5% Annualized Using Options
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
ACELYRIN Becomes Oversold (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024.
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acelyrin (NASDAQ:SLRN) just reported results for the first quarter of 2024.Acel...
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month;...
ACELYRIN, INC. Announces Leadership Transition
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...